FDA approves lower-cost alternative to biotech drug Humira

WASHINGTON (AP) - Federal regulators have approved the first alternative version of the second-biggest selling drug in the world, AbbVie's Humira, a blockbuster injection used to treat rheumatoid arthritis and other inflammatory diseases.

The Food and Drug Administration cleared the near-copy of the drug, dubbed Amjevita, developed by Amgen Inc.

FDA approves lower-cost alternative to biotech drug Humira